首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1289780

全球T細胞淋巴瘤市場 - 2023-2030年

Global T-Cell Lymphoma Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

T細胞淋巴瘤市場在2022年達到14.852億美元，預計到2030年將見證有利可圖的成長，達到27.878億美元。在預測期間（2023-2030年），T細胞淋巴瘤市場預計將呈現8.4%的複合年成長率。

T細胞淋巴瘤分為兩種類型：外周T細胞淋巴瘤和T細胞淋巴細胞淋巴瘤。 T細胞淋巴瘤可通過化療、放療、免疫療法、抗病毒藥物治療、幹細胞移植和其他療法進行治療。

T細胞淋巴瘤市場的成長還歸因於輻射促使的淋巴瘤癌症發病率的上升，T細胞淋巴瘤特異性療法數量的增加，以及自身免疫性疾病促使的淋巴瘤風險。

市場動態

全球癌症患病率的增加

癌症患病率的增加是影響T細胞淋巴瘤市場機會的驅動因素之一。另一個因素是醫療基礎設施投資的增加和老年人口的增加，促使T細胞淋巴瘤市場的擴大。

根據世衛組織的數據，癌症是全球死亡的主要原因，2020年將有近1000萬人死亡，或近六分之一的死亡。每年約有40萬名兒童患上癌症。最常見的癌症在各國之間有所不同。

治療費用高，持續時間長

由於其獨特的作用機制，T細胞淋巴瘤的治療非常昂貴，收集和製造過程也增加了總成本。治療的高額費用也因病人的疾病程度和根據病人標準所需的治療水平而有所不同。

COVID-19影響分析

由於癌症治療服務的中斷和癌症治療的臨床試驗的停止，COVID-19大流行對預測期內的全球T細胞淋巴瘤市場趨勢產生了負面影響。

由於COVID-19的流行，皮膚淋巴瘤患者錯過接受關鍵的診斷測試和治療的風險增加，因為他們難以進入醫院或缺乏可用的醫療資源。

Market Overview

The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

Market Dynamics

Increase in Prevalence of Cancer Worldwide

The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.

High Cost and Long Duration of Treatment

Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share

Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.

Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.

Geographical Analysis

North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market

The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.

Competitive Landscape

The major global players include: Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.

Why Purchase the Report?
To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increase in the prevalence of cancer worldwide
- 4.1.2. Restraints
  - 4.1.2.1. High cost and long duration of treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Class

7.1. Peripheral T Cell Lymphoma
7.2. Cutaneous T Cell Lymphoma
7.3. Anaplastic Large Cell Lymphoma
7.4. Others

8. By Treatment

8.1. Radiotherapy
8.2. Chemotherapy
8.3. Targeted Therapy
8.4. Surgery
8.5. Stem Cell Transplantation
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1.1. The U.S.
  - 9.2.5.1.2. Canada
  - 9.2.5.1.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1.1. Germany
  - 9.3.5.1.2. The UK
  - 9.3.5.1.3. France
  - 9.3.5.1.4. Italy
  - 9.3.5.1.5. Spain
  - 9.3.5.1.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1.1. Brazil
  - 9.4.5.1.2. Argentina
  - 9.4.5.1.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1.1. China
  - 9.5.5.1.2. India
  - 9.5.5.1.3. Japan
  - 9.5.5.1.4. Australia
  - 9.5.5.1.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country